×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| CAPLIN POINT LABORATORIES LTD. | 2146.0 | 858.9 | 1825.7 | 11.26 | 16,774 | 29.7 |
| NATCO PHARMA LTD. | 12523.0 | 4641.0 | 11927.0 | 25.91 | 15106 | 8.89 |
| Rainbow Children's Medicare Li | 3540.33 | 517.2 | 3347.48 | 5.09 | 15046 | 58.4 |
Caplin Point Laboratories Ltd., with Security Code 524742, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144.7 | 173.7 | 179.2 | 132.8 | 139.4 | 185.6 | 207.9 | 185.2 | 173.6 | 182.6 |
| Expenses | 79.8 | 97.0 | 89.8 | 69.5 | 81.7 | 104.3 | 109.8 | 107.8 | 98.6 | 96.0 |
| Operating Profit | 64.9 | 76.6 | 89.5 | 63.3 | 57.7 | 81.4 | 98.2 | 77.4 | 75.0 | 86.6 |
| OPM % | 44.84% | 44.12% | 49.91% | 47.67% | 41.38% | 43.84% | 47.21% | 41.78% | 43.22% | 47.44% |
| Other Income | 12.2 | 27.3 | 24.5 | 17.9 | 36.2 | 21.5 | 43.0 | 28.8 | 41.3 | 32.0 |
| Interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Depreciation | 6.3 | 6.7 | 6.7 | 6.8 | 6.9 | 6.2 | 6.5 | 6.0 | 6.1 | 6.1 |
| Profit before tax | 70.8 | 97.2 | 107.2 | 74.4 | 86.9 | 96.7 | 134.7 | 100.2 | 110.2 | 112.5 |
| Tax % | -23.2% | -21.5% | -23.4% | -25.5% | -19.6% | -25% | -21.5% | -25.4% | -21.4% | 23.6% |
| Net Profit | 54.3 | 76.3 | 82.1 | 55.5 | 69.9 | 72.5 | 105.7 | 74.7 | 86.5 | 85.9 |
| EPS in Rs | 7.09 | 9.99 | 10.76 | 7.29 | 9.14 | 9.5 | 13.85 | 9.77 | 0 | 11.26 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 372.1 | 389.3 | 395.3 | 410.1 | 435.5 | 453.2 | 459.0 | 483.1 | 493.0 | 502.5 |
| Expenses | 262.7 | 265.4 | 268.7 | 272.7 | 293.2 | 308.0 | 307.2 | 318.4 | 330.7 | 334.4 |
| Operating Profit | 109.4 | 123.9 | 126.6 | 137.4 | 142.3 | 145.2 | 151.8 | 164.7 | 162.3 | 168.1 |
| OPM % | 29.4% | 31.84% | 32.03% | 33.51% | 32.67% | 32.04% | 33.08% | 34.08% | 32.92% | 33.45% |
| Other Income | 14.2 | 11.5 | 12.0 | 20.4 | 17.2 | 17.4 | 18.6 | 20.8 | 31.4 | 25.7 |
| Interest | 0.4 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 |
| Depreciation | 11.4 | 11.1 | 11.4 | 11.8 | 13.9 | 16.4 | 16.0 | 16.8 | 16.2 | 17.0 |
| Profit before tax | 111.7 | 124.0 | 127.0 | 145.9 | 145.4 | 146.0 | 154.4 | 168.5 | 177.3 | 176.6 |
| Tax % | -12.8% | -18.4% | -17.9% | -20.5% | -17.6% | -17% | -19.1% | -22.3% | -21% | -17.7% |
| Net Profit | 97.4 | 101.2 | 104.2 | 116.1 | 119.8 | 121.2 | 124.9 | 130.8 | 140.1 | 145.3 |
| EPS in Rs | 12.75 | 13.33 | 13.55 | 15.06 | 15.39 | 15.9 | 16.24 | 17.12 | 18.19 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 7% |
| 3 Years: | 13% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 12% |
| 3 Years: | 22% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 48% |
| 3 Years: | 46% |
| 1 Year: | 75% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 18% |
| 3 Years: | 15% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 20% |
| 3 Years: | 21% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 48% |
| 3 Years: | 46% |
| 1 Year: | 75% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|